Effect of Heart Rate Control With Esmolol on Hemodynamic and Clinical Outcomes in Patients With Septic Shock: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: β-Blocker therapy may control heart rate and attenuate the deleterious effects of β-adrenergic receptor stimulation in septic shock. However, β-Blockers are not traditionally used for this condition and may worsen cardiovascular decompensation related through negative inotropic and hypotensive effects. OBJECTIVE: To investigate the effect of the short-acting β-blocker esmolol in patients with severe septic shock. DESIGN, SETTING, AND PATIENTS: Open-label, randomized phase 2 study, conducted in a university hospital intensive care unit (ICU) between November 2010 and July 2012, involving patients in septic shock with a heart rate of 95/min or higher requiring high-dose norepinephrine to maintain a mean arterial pressure of 65 mm Hg or higher. INTERVENTIONS: We randomly assigned 77 patients to receive a continuous infusion of esmolol titrated to maintain heart rate between 80/min and 94/min for their ICU stay and 77 patients to standard treatment. MAIN OUTCOMES AND MEASURES: Our primary outcome was a reduction in heart rate below the predefined threshold of 95/min and to maintain heart rate between 80/min and 94/min by esmolol treatment over a 96-hour period. Secondary outcomes included hemodynamic and organ function measures; norepinephrine dosages at 24, 48, 72, and 96 hours; and adverse events and mortality occurring within 28 days after randomization. RESULTS: Targeted heart rates were achieved in all patients in the esmolol group compared with those in the control group. The median AUC for heart rate during the first 96 hours was -28/min (IQR, -37 to -21) for the esmolol group vs -6/min (95% CI, -14 to 0) for the control group with a mean reduction of 18/min (P < .001). For stroke volume index, the median AUC for esmolol was 4 mL/m2 (IQR, -1 to 10) vs 1 mL/m2 for the control group (IQR, -3 to 5; P = .02), whereas the left ventricular stroke work index for esmolol was 3 mL/m2 (IQR, 0 to 8) vs 1 mL/m2 for the control group (IQR, -2 to 5; P = .03). For arterial lactatemia, median AUC for esmolol was -0.1 mmol/L (IQR, -0.6 to 0.2) vs 0.1 mmol/L for the control group (IQR, -0.3 for 0.6; P = .007); for norepinephrine, -0.11 μg/kg/min (IQR, -0.46 to 0.02) for the esmolol group vs -0.01 μg/kg/min (IQR, -0.2 to 0.44) for the control group (P = .003). Fluid requirements were reduced in the esmolol group: median AUC was 3975 mL/24 h (IQR, 3663 to 4200) vs 4425 mL/24 h(IQR, 4038 to 4775) for the control group (P < .001). We found no clinically relevant differences between groups in other cardiopulmonary variables nor in rescue therapy requirements. Twenty-eight day mortality was 49.4% in the esmolol group vs 80.5% in the control group (adjusted hazard ratio, 0.39; 95% CI, 0.26 to 0.59; P < .001). CONCLUSIONS AND RELEVANCE: For patients in septic shock, open-label use of esmolol vs standard care was associated with reductions in heart rates to achieve target levels, without increased adverse events. The observed improvement in mortality and other secondary clinical outcomes warrants further investigation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01231698.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
Le Gall, J.-R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.270.24.2957 · Cited by 7,773
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Analysis of serial measurements in medical research.
Matthews, J. N., Altman, D. G., Campbell, M. J., & Royston, P. (1990) · BMJ · doi:10.1136/bmj.300.6719.230 · Cited by 3,136
Mechanisms of sepsis-induced cardiac dysfunction
Rudiger, A., & Singer, M. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000266683.64081.02 · Cited by 704
Self-citationSurvival plots of time-to-event outcomes in clinical trials: good practice and pitfalls
Pocock, S. J., Clayton, T. C., & Altman, D. G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08594-x · Cited by 513
PARKER, M. M., SHELHAMER, J. H., NATANSON, C., ALLING, D. W., & PARRILLO, J. E. (1987) · Critical Care Medicine · doi:10.1097/00003246-198710000-00006 · Cited by 505
Testing for baseline balance in clinical trials
Senn, S. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131703 · Cited by 503 · cited 2×
“001 Length of ICU stay, d Median (IQR) 19 (11-27) 14 (7-25) .”
Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress
Dünser, M. W., & Hasibeder, W. R. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609340519 · Cited by 488
Park, J., Kang, S., Song, J., Kim, H. K., Lim, C. M., Kang, D., & Koh, Y. (2005) · CHEST Journal · doi:10.1378/chest.128.1.296 · Cited by 317
Arginine vasopressin in 316 patients with advanced vasodilatory shock*
Luckner, G., Dünser, M. W., Jochberger, S., Mayr, V. D., Wenzel, V., Ulmer, H., Schmid, S., Knotzer, H., Pajk, W., Hasibeder, W., et al. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000186749.34028.40 · Cited by 316
Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study
Schmittinger, C. A., Torgersen, C., Luckner, G., Schröder, D. C. H., Lorenz, I., & Dünser, M. W. (2012) · Intensive Care Medicine · doi:10.1007/s00134-012-2531-2 · Cited by 246
Ackland, G. L., Yao, S. T., Rudiger, A., Dyson, A., Stidwill, R. P., Poputnikov, D. M., Singer, M., & Gourine, A. V. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181c03dfa · Cited by 176
Self-citationBench-to-bedside review: β-Adrenergic modulation in sepsis
de Montmollin, E., Aboab, J., Mansart, A., & Annane, D. (2009) · Critical Care · doi:10.1186/cc8026 · Cited by 158
Catecholamine treatment for shock—equally good or bad?
Singer, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61317-8 · Cited by 129
Self-citationSander, O., Welters, I. D., Foëx, P., & Sear, J. W. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000150028.64264.14 · Cited by 128
Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression
Schmittinger, C. A., Dünser, M. W., Haller, M., Ulmer, H., Luckner, G., Torgersen, C., Jochberger, S., & Hasibeder, W. R. (2008) · Critical Care · doi:10.1186/cc6976 · Cited by 98
The ups and downs of heart rate
Magder, S. A. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318232e50c · Cited by 81
Beta-1 blocker improves survival of septic rats through preservation of gut barrier function
Mori, K., Morisaki, H., Yajima, S., Suzuki, T., Ishikawa, A., Nakamura, N., Innami, Y., & Takeda, J. (2011) · Intensive Care Medicine · doi:10.1007/s00134-011-2326-x · Cited by 79
Characteristics of patients receiving vasopressors
Benbenishty, J. S., Weissman, C., Sprung, C. L., Brodsky-Israeli, M., & Weiss, Y. (2010) · Heart & Lung · doi:10.1016/j.hrtlng.2010.04.007 · Cited by 57
Nuding, S., Ebelt, H., Hoke, R. S., Krummenerl, A., Wienke, A., Müller‐Werdan, U., & Werdan, K. (2011) · Clinical Research in Cardiology · doi:10.1007/s00392-011-0323-2 · Cited by 48
Cited by
Sepsis: pathophysiology and clinical management
Gotts, J. E., & Matthay, M. A. (2016) · BMJ · doi:10.1136/bmj.i1585 · Cited by 1,243
Sepsis: a roadmap for future research
Cohen, J., Vincent, J.-L., Adhikari, N. K. J., Machado, F. R., Angus, D. C., Calandra, T., Jaton, K., Giulieri, S., Delaloye, J., Opal, S., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70112-x · Cited by 992
EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure
Wendon, J., Cordoba, J., Dhawan, A., Larsen, F. S., Manns, M., Nevens, F., Samuel, D., Simpson, K. J., Yaron, I., & Bernardi, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.003 · Cited by 917
Angiotensin II for the Treatment of Vasodilatory Shock
Khanna, A., English, S. W., Wang, X. S., Ham, K., Tumlin, J., Szerlip, H., Busse, L. W., Altaweel, L., Albertson, T. E., Mackey, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704154 · Cited by 916
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Metadata
- Authors
- Morelli, A., Ertmer, C., Westphal, M., Rehberg, S., Kampmeier, T., Ligges, S., Orecchioni, A., D’Egidio, A., D’Ippoliti, F., Raffone, C., Venditti, M., Guarracino, F., Girardis, M., Tritapepe, L., Pietropaoli, P., Mebazaa, A., & Singer, M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-10-23
- Volume
- 310
- Issue
- 16
- Pages
- 1683
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2143034699
- Cited by
- 720
- References
- 21
- FWCI
- 42.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.